Sonoma Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 73/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 14.80.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sonoma Pharmaceuticals Inc's Score
Industry at a Glance
Industry Ranking
73 / 158
Overall Ranking
181 / 4562
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
14.800
Target Price
+322.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sonoma Pharmaceuticals Inc Highlights
StrengthsRisks
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.29M.
Undervalued
The company’s latest PE is -1.81, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 106.22K shares, increasing 19.12% quarter-over-quarter.
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Ticker SymbolSNOA
CompanySonoma Pharmaceuticals Inc
CEOTrombly (Amy)
Websitehttps://sonomapharma.com/
FAQs
What is the current price of Sonoma Pharmaceuticals Inc (SNOA)?
The current price of Sonoma Pharmaceuticals Inc (SNOA) is 3.630.
What is the symbol of Sonoma Pharmaceuticals Inc?
The ticker symbol of Sonoma Pharmaceuticals Inc is SNOA.
What is the 52-week high of Sonoma Pharmaceuticals Inc?
The 52-week high of Sonoma Pharmaceuticals Inc is 6.920.
What is the 52-week low of Sonoma Pharmaceuticals Inc?
The 52-week low of Sonoma Pharmaceuticals Inc is 1.750.
What is the market capitalization of Sonoma Pharmaceuticals Inc?
The market capitalization of Sonoma Pharmaceuticals Inc is 5.99M.
What is the net income of Sonoma Pharmaceuticals Inc?
The net income of Sonoma Pharmaceuticals Inc is -3.46M.
Is Sonoma Pharmaceuticals Inc (SNOA) currently rated as Buy, Hold, or Sell?
According to analysts, Sonoma Pharmaceuticals Inc (SNOA) has an overall rating of --, with a price target of 14.800.
What is the Earnings Per Share (EPS TTM) of Sonoma Pharmaceuticals Inc (SNOA)?
The Earnings Per Share (EPS TTM) of Sonoma Pharmaceuticals Inc (SNOA) is -2.007.